A Randomized, Dose-Ranging, Double Blind Study of Lidocaine Hydrochloride and/or Hydrocortisone Acetate (Alone or in Combination) in the 14-Day Twice-Daily Treatment of Grade I or II Hemorrhoids

Trial Profile

A Randomized, Dose-Ranging, Double Blind Study of Lidocaine Hydrochloride and/or Hydrocortisone Acetate (Alone or in Combination) in the 14-Day Twice-Daily Treatment of Grade I or II Hemorrhoids

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Hydrocortisone (Primary) ; Lidocaine (Primary) ; Lidocaine/hydrocortisone (Primary)
  • Indications Haemorrhoids
  • Focus Therapeutic Use
  • Sponsors Citius Pharmaceuticals LLC
  • Most Recent Events

    • 06 Mar 2018 According to a Citius Pharmaceuticals media release, the company held a Type C meeting with the FDA to discuss the results of the Phase 2a study and to obtain the Agencys view on development plans to support the potential formulation change for the planned Phase 2b study.
    • 04 Feb 2016 New trial record
    • 01 Feb 2016 According to a Citius Pharmaceuticals media release, the company announced results of phase IIa trial of Hydrocortisone and Lidocaine combination cream in patients with grade I and II Hemorrhoids.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top